Pluvicto is the country’s first regulatory authority-approved radioligand therapy for eligible patients with prostate-specific membrane antigen (PSMA)-positive prostate cancer, Novartis India said in a statement.
Designed to precisely target prostate cancer cells while minimising exposure to healthy tissues, Pluvicto introduces a new treatment approach for metastatic prostate cancer, a disease that continues to place a significant physical and emotional burden on patients and families across India, it added.
“India is a priority market for Novartis, with growing momentum in precision oncology and advanced cancer care. The introduction of Pluvicto marks a meaningful step forward, bringing globally approved innovation closer to patients who need more targeted treatment options,” Novartis, Region Head Asia Pacific, Middle East Africa, Judith Love said.
Novartis India Country President and Managing Director, Amitabh Dube, said, “Pluvicto will be made available through select hospitals and nuclear medicine centres across India as part of Novartis’ partnership-led approach for bringing radioligand therapies to India.”
